Improving Outcomes in Childhood and Young Adult Cancers in Low- and Middle-Income Countries A Multicenter Retrospective Study on Treatment Failure and Toxicity
Led by Resonance, Inc. · Updated on 2026-09-29
18000
Participants Needed
7
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate cancer treatment outcomes among children, adolescents, and young adults aged 0 to 21 years living in low- and middle-income countries LMICs. It focuses on acute lymphoblastic leukemia ALL and lymphoblastic lymphoma LBL, conditions where treatment success varies widely between high-income and LMICs due to factors like delayed diagnosis and limited access to quality care. The study seeks to inform future efforts to improve cancer care and reduce treatment failures in these regions.
The study involves a retrospective review of medical records from participating oncology centers in countries including Guatemala, Honduras, El Salvador, Armenia, and Tanzania. It includes patients with any type of cancer diagnosis who received substantial anti-cancer treatment such as chemotherapy, surgery, radiation, or immunotherapy. Special attention is given to patients with ALL or LBL to assess therapy-related toxicities and treatment outcomes over a three-year follow-up period.
Participants medical records will be analyzed to estimate the incidence of treatment failure, including relapse or progression, and therapy-related severe toxicities. Data on event-free survival and overall survival will also be collected. No experimental treatments are administered, as this is a purely observational study. The study period covers up to three years from each patients cancer diagnosis, using existing health data to better understand treatment challenges and outcomes in LMICs.
CONDITIONS
Brief Title
CAYA Cancer Retrospective Cohort Study
Research Team
G
Gabriela Villanueva, MD.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Participants willing and able to provide informed consent or assent with guardian consent.
Confirmed diagnosis of any cancer within 15 years prior to site activation.
Age between 0 and 21 years at diagnosis.
Received substantial anti-cancer treatment such as chemotherapy, surgery, radiation, or immunotherapy at a participating center.
Medical records must be available and accessible for review.
You will not qualify if you...
Patients who only had consultation visits without primary anti-cancer treatment at the participating center.
Patients who only underwent pathology, radiology, or other diagnostic evaluations without treatment.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (retrospective data review)
Data Collection
Duration - Up to 3 years from diagnosis
Researchers review medical records of participants diagnosed with cancer to collect information on treatment failures and therapy-related toxicities over a three-year period from diagnosis.
No visits; retrospective record review only
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Study of Escalating Doses of 211-At-BC8-B10 Followed by Donor Stem Cell Transplant for High-Risk AML, ALL, MDS, or Mixed-Phenotype Acute Leukemia
Phase I Dose Escalation Study of 225Ac-DOTA-Anti-CD38 Daratumumab Added to Fludarabine, Melphalan, and Targeted Total Marrow and Lymphoid Irradiation Before Donor Stem Cell Transplant for High-Risk Leukemia and Myelodysplastic Syndrome
Randomized Study of New Immunotherapies and Stem Cell Transplantation for Adults Aged 18-65
with Acute Lymphoblastic Leukemia
Virtual Nutrition Education to Prevent Weight Gain During Maintenance Chemotherapy in Children and Adolescents with Acute Lymphoblastic Leukemia
Open-label Multi-center Study of MK-1045 for Adults and Children With Precursor B-cell Acute Lymphoblastic Leukemia
Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units in Children and Adults with Blood Cancers and Related Disorders
Evaluating Next-Generation Sequencing and B-Cell Recovery Monitoring to Guide Post-CART Management in Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia
Phase 1 Study of FIT-CD19-CAR-T Cell Therapy Infusion with Chemotherapy in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Phase 1 Dose Escalation and Expansion Study of Orca-Q Engineered Donor Graft in Blood Cancer Patients Undergoing Allogeneic Stem Cell Transplantation
Study of WU-CART-007 Anti-CD7 CAR-T Cell Therapy for RelapsedRefractory T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment.
Guillermo Chantada, Catherine G Lam, Scott C Howard